133 related articles for article (PubMed ID: 37170983)
21. The p60c-src family of protein-tyrosine kinases: structure, regulation, and function.
Brickell PM
Crit Rev Oncog; 1992; 3(4):401-46. PubMed ID: 1384720
[TBL] [Abstract][Full Text] [Related]
22. Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects.
Garcia-Gomez A; Ocio EM; Crusoe E; Santamaria C; Hernández-Campo P; Blanco JF; Sanchez-Guijo FM; Hernández-Iglesias T; Briñón JG; Fisac-Herrero RM; Lee FY; Pandiella A; San Miguel JF; Garayoa M
PLoS One; 2012; 7(4):e34914. PubMed ID: 22539950
[TBL] [Abstract][Full Text] [Related]
23. Development of the phenylpyrazolo[3,4-
Lee HJ; Pham PC; Pei H; Lim B; Hyun SY; Baek B; Kim B; Kim Y; Kim MH; Kang NW; Min HY; Kim DD; Lee J; Lee HY
Theranostics; 2021; 11(4):1918-1936. PubMed ID: 33408789
[No Abstract] [Full Text] [Related]
24. SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer.
Saad F; Lipton A
Cancer Treat Rev; 2010 Apr; 36(2):177-84. PubMed ID: 20015594
[TBL] [Abstract][Full Text] [Related]
25. Src inhibitors in lung cancer: current status and future directions.
Rothschild SI; Gautschi O; Haura EB; Johnson FM
Clin Lung Cancer; 2010 Jul; 11(4):238-42. PubMed ID: 20630825
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
Montero JC; Seoane S; Ocaña A; Pandiella A
Clin Cancer Res; 2011 Sep; 17(17):5546-52. PubMed ID: 21670084
[TBL] [Abstract][Full Text] [Related]
27. Nonreceptor tyrosine kinases in prostate cancer.
Chang YM; Kung HJ; Evans CP
Neoplasia; 2007 Feb; 9(2):90-100. PubMed ID: 17357254
[TBL] [Abstract][Full Text] [Related]
28. Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity.
Muthuswamy SK; Siegel PM; Dankort DL; Webster MA; Muller WJ
Mol Cell Biol; 1994 Jan; 14(1):735-43. PubMed ID: 7903421
[TBL] [Abstract][Full Text] [Related]
29. Src as a therapeutic target in men with prostate cancer and bone metastases.
Saad F
BJU Int; 2009 Feb; 103(4):434-40. PubMed ID: 19154462
[TBL] [Abstract][Full Text] [Related]
30. Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress.
Kopetz S; Lesslie DP; Dallas NA; Park SI; Johnson M; Parikh NU; Kim MP; Abbruzzese JL; Ellis LM; Chandra J; Gallick GE
Cancer Res; 2009 May; 69(9):3842-9. PubMed ID: 19383922
[TBL] [Abstract][Full Text] [Related]
31. Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.
Formisano L; D'Amato V; Servetto A; Brillante S; Raimondo L; Di Mauro C; Marciano R; Orsini RC; Cosconati S; Randazzo A; Parsons SJ; Montuori N; Veneziani BM; De Placido S; Rosa R; Bianco R
Oncotarget; 2015 Sep; 6(28):26090-103. PubMed ID: 26325669
[TBL] [Abstract][Full Text] [Related]
32. Src family kinases differentially influence glioma growth and motility.
Lewis-Tuffin LJ; Feathers R; Hari P; Durand N; Li Z; Rodriguez FJ; Bakken K; Carlson B; Schroeder M; Sarkaria JN; Anastasiadis PZ
Mol Oncol; 2015 Nov; 9(9):1783-98. PubMed ID: 26105207
[TBL] [Abstract][Full Text] [Related]
33. Development of 2'-aminospiro [pyrano[3,2-c]quinoline]-3'-carbonitrile derivatives as non-ATP competitive Src kinase inhibitors that suppress breast cancer cell migration and proliferation.
Ramadan M; A M M Elshaier Y; Aly AA; Abdel-Aziz M; Fathy HM; Brown AB; Pridgen JR; Dalby KN; Kaoud TS
Bioorg Chem; 2021 Nov; 116():105344. PubMed ID: 34598088
[TBL] [Abstract][Full Text] [Related]
34. Disulfiram Synergizes with SRC Inhibitors to Suppress the Growth of Pancreatic Ductal Adenocarcinoma Cells in Vitro and in Vivo.
Li Z; Xie X; Tan G; Xie F; Liu N; Li W; Sun X
Biol Pharm Bull; 2021; 44(9):1323-1331. PubMed ID: 34471060
[TBL] [Abstract][Full Text] [Related]
35. Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib.
Serrels A; Macpherson IR; Evans TR; Lee FY; Clark EA; Sansom OJ; Ashton GH; Frame MC; Brunton VG
Mol Cancer Ther; 2006 Dec; 5(12):3014-22. PubMed ID: 17148760
[TBL] [Abstract][Full Text] [Related]
36. Targeting Upstream Kinases of STAT3 in Human Medulloblastoma Cells.
Wei J; Ma L; Li C; Pierson CR; Finlay JL; Lin J
Curr Cancer Drug Targets; 2019; 19(7):571-582. PubMed ID: 30332965
[TBL] [Abstract][Full Text] [Related]
37. Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases.
Liu Y; Karaca M; Zhang Z; Gioeli D; Earp HS; Whang YE
Oncogene; 2010 Jun; 29(22):3208-16. PubMed ID: 20383201
[TBL] [Abstract][Full Text] [Related]
38. The role of Src in prostate cancer.
Fizazi K
Ann Oncol; 2007 Nov; 18(11):1765-73. PubMed ID: 17426060
[TBL] [Abstract][Full Text] [Related]
39. The role of lysyl oxidase in SRC-dependent proliferation and metastasis of colorectal cancer.
Baker AM; Cox TR; Bird D; Lang G; Murray GI; Sun XF; Southall SM; Wilson JR; Erler JT
J Natl Cancer Inst; 2011 Mar; 103(5):407-24. PubMed ID: 21282564
[TBL] [Abstract][Full Text] [Related]
40. CagA Phosphorylation in Helicobacter pylori-Infected B Cells Is Mediated by the Nonreceptor Tyrosine Kinases of the Src and Abl Families.
Krisch LM; Posselt G; Hammerl P; Wessler S
Infect Immun; 2016 Sep; 84(9):2671-80. PubMed ID: 27382024
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]